A Phase 2/3 interventional study of Brexpiprazole and Placebo in Agitation Associated With Dementia of the Alzheimer's Type, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-11-14.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Dementia by Otsuka Holdings Co., Ltd. — none open to participants now, none under way, none of them phase 3. Dementia · Otsuka Holdings Co., Ltd..
Among the 11 studies in Dementia by Otsuka Holdings Co., Ltd., this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2018, is the only one in phase 2/3, and was the 10th registered.
2,375 studies on the registry are indexed under Dementia; 574 are open to participants now.
Browse Dementia studies →None of the 11 studies in Dementia by Otsuka Holdings Co., Ltd. is open now. The open studies under Dementia, anywhere →
Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.
This study: 55 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 9 · Phase 4 1
First in 2003; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 410 is above the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 377 across the 10 interventional studies, 450 across the 1 observational. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Dementia by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the superiority of brexpiprazole 1 mg or 2 mg over placebo after a 10-week treatment regimen for agitation associated with dementia of the Alzheimer's type in patients who require medication, and to investigate the safety of brexpiprazole and identify the optimum dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who satisfy both of the following diagnostic criteria:
Exclusion Criteria:
Patients diagnosed with any of the following disorders according to DSM-5:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 1mg/day Once daily for 10 weeks
Drug: Brexpiprazole
Drug: 2mg/day Once daily for 10 weeks
Drug: Brexpiprazole
Drug: Placebo (0mg/day) Once daily for 10 weeks
Drug: Placebo
Drug: 1 tablet /day Once daily for 10 weeks
Placebo: 1 tablet /day Once daily for 10 weeks
Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing.
The CMAI assessed the frequency of agitated behaviors in elderly persons, such as hitting, cursing, and restlessness. It consisted of 29 items all rated on a 1 to 7 scale with 1 being the "best" rating and 7 being the "worst" rating. The minimum possible CMAI total score was 29, and the maximum possible CMAI total score was 203. A decrease in score indicated improvement in symptoms.
Time frame: Baseline and 10 weeks first dose, on average 10 weeks
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 10 Weeks After Dosing.
The CGI-S was used to rate the severity of agitation. Scores were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A decrease in score indicated improvement in symptoms.
Time frame: Baseline and 10 weeks first dose, on average 10 weeks
Clinical Global Impression of Improvement (CGI-I) Score at 10 Weeks After Dosing.
The CGI-I Scale was clinician-rated scale which assessed the total improvement of the patient's condition compared to that at baseline. Scores range from 0 to 7: 0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicate worse condition.
Time frame: Baseline and 10 weeks first dose, on average 10 weeks
| Milestone | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo |
|---|---|---|---|
| Started | 112 | 149 | 149 |
| Completed | 83 | 102 | 116 |
| Not completed | 29 | 47 | 33 |
| Withdrew: Adverse event | 14 | 38 | 25 |
| Withdrew: Lack of efficacy | 2 | 1 | 1 |
| Withdrew: Physician decision | 7 | 4 | 4 |
| Withdrew: Protocol violation | 1 | 2 | 1 |
| Withdrew: Withdrawal by legal representative | 2 | 1 | 1 |
| Withdrew: Withdrawal by care giver | 2 | 0 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 1 | 0 |
The CMAI assessed the frequency of agitated behaviors in elderly persons, such as hitting, cursing, and restlessness. It consisted of 29 items all rated on a 1 to 7 scale with 1 being the "best" rating and 7 being the "worst" rating. The minimum possible CMAI total score was 29, and the maximum possible CMAI total score was 203. A decrease in score indicated improvement in symptoms.
| units on a scale | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing. | -11.7 ± 1.20 | -15.2 ± 1.05 | -8.0 ± 1.03 |
The CGI-S was used to rate the severity of agitation. Scores were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A decrease in score indicated improvement in symptoms.
| units on a scale | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 10 Weeks After Dosing. | -1.0 ± 0.1 | -1.4 ± 0.09 | -0.6 ± 0.09 |
The CGI-I Scale was clinician-rated scale which assessed the total improvement of the patient's condition compared to that at baseline. Scores range from 0 to 7: 0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicate worse condition.
| units on a scale | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo |
|---|---|---|---|
| Clinical Global Impression of Improvement (CGI-I) Score at 10 Weeks After Dosing. | 3.1 ± 1.3 | 2.6 ± 1.2 | 3.5 ± 1.4 |
Collected over Adverse events were monitored from signing of the informed consent form until follow-up for up to 35 days after the final day of IMP administration, on average 19 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole 1 mg | 2/112 (1.8%) | 7/112 (6.3%) | 77/112 (68.8%) |
| Brexpiprazole 2 mg | 0/149 (0%) | 9/149 (6%) | 113/149 (75.8%) |
| Placebo | 0/149 (0%) | 7/149 (4.7%) | 93/149 (62.4%) |
| Event | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo |
|---|---|---|---|
| Pneumonia aspirationInfections and infestations | 2/112 | 2/149 | 0/149 |
| AgitationPsychiatric disorders | 1/112 | 0/149 | 2/149 |
| Cardiac deathGeneral disorders | 1/112 | 0/149 | 0/149 |
| Hepatic massHepatobiliary disorders | 1/112 | 0/149 | 0/149 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/112 | 1/149 | 0/149 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/112 | 1/149 | 0/149 |
| IIIrd nerve paralysisNervous system disorders | 1/112 | 0/149 | 0/149 |
| AnaemiaBlood and lymphatic system disorders | 0/112 | 1/149 | 0/149 |
| PneumoniaInfections and infestations | 0/112 | 0/149 | 1/149 |
| Femur fractureInjury, poisoning and procedural complications | 0/112 | 0/149 | 1/149 |
| Event | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo |
|---|---|---|---|
| SomnolenceNervous system disorders | 9/112 | 24/149 | 3/149 |
| InsomniaPsychiatric disorders | 16/112 | 18/149 | 22/149 |
| BradykinesiaNervous system disorders | 8/112 | 20/149 | 0/149 |
| ContusionInjury, poisoning and procedural complications | 9/112 | 9/149 | 19/149 |
| Salivary hypersecretionGastrointestinal disorders | 1/112 | 18/149 | 1/149 |
| Muscle rigidityMusculoskeletal and connective tissue disorders | 9/112 | 16/149 | 1/149 |
| AgitationPsychiatric disorders | 2/112 | 4/149 | 16/149 |
| Gait disturbanceGeneral disorders | 5/112 | 15/149 | 1/149 |
| FallInjury, poisoning and procedural complications | 9/112 | 14/149 | 9/149 |
| PyrexiaGeneral disorders | 9/112 | 11/149 | 8/149 |
| Age, Categorical(Participants) | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 4 | 4 | 15 |
| >=65 years | 105 | 145 | 145 | 395 |
| Age, Continuous(years) | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 79.3 ± 7.4 | 80.2 ± 6.4 | 80.3 ± 6.7 | 80.0 ± 6.8 |
| Sex: Female, Male(Participants) | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 71 | 105 | 87 | 263 |
| Male | 41 | 44 | 62 | 147 |
| Race (NIH/OMB)(Participants) | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 112 | 149 | 149 | 410 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo | Total |
|---|---|---|---|---|
| Japan | 112 | 149 | 149 | 410 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.
Ran from Aug 2018 to primary completion in Apr 2023, 56 months.
Results were first posted in Nov 2024, 1 year 6 months after primary completion.
Of 20 phase 2/3 interventional studies under Dementia, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 59. This study's 56 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Co., Ltd. →